Nozawa identified increased expression of CTGF in serum from 39 patients with RA when compared to patients with osteoarthritis (OA) and further confirmed that CTGF could enhance the activity of osteoclasts by stimulating integrin protein αvβ3 to aggravate bone destruction [12]. This evidence concerns the gene CCN2 and osteoarthritis.